医学分子生物学杂志
醫學分子生物學雜誌
의학분자생물학잡지
FOREIGN MEDICAL SCIENCES
2015年
2期
69-74
,共6页
TAT-凋亡素%雷帕霉素%联合治疗%胶质瘤细胞
TAT-凋亡素%雷帕黴素%聯閤治療%膠質瘤細胞
TAT-조망소%뢰파매소%연합치료%효질류세포
TAT-apoptin%rapamycin%combination therapy%glioma
目的：研究雷帕霉素(Rapamycin, Rapa)和凋亡素(TAT-apoptin, T-ap)联合应用对神经胶质瘤的治疗作用。方法用 MTT 实验比较 Rapa、 TAT-apoptin 单用和联合应用对 U87细胞增殖的影响； AO/EB 荧光染色与流式细胞仪检测对 U87细胞凋亡的影响；建立裸鼠 C6胶质瘤皮下移植模型,计算 Rapa、TAT-apoptin 单独及联合作用下的抑瘤率。结果 Rapa 与 TAT-apoptin 单独用药均能抑制 U87细胞的增殖,呈剂量依赖性,联合用药组细胞增殖率明显低于单独用药组(P ﹤0.05)；联合用药组凋亡状态比单独用药更明显,呈晚期凋亡形态,细胞凋亡率显著高于单独用药组(P ﹤0.01)；在体内实验中,联合用药组抑瘤率为65.5％,雷帕霉素与 TAT-凋亡素单独用药抑瘤率分别为29.59％,24.4％,前者比后者高1倍(P ﹤0.05)。结论 Rapa 与 TAT-ap 联合用药可增强对胶质瘤细胞增殖的抑制作用,促进胶质瘤细胞的凋亡,产生协同的抗肿瘤作用。
目的：研究雷帕黴素(Rapamycin, Rapa)和凋亡素(TAT-apoptin, T-ap)聯閤應用對神經膠質瘤的治療作用。方法用 MTT 實驗比較 Rapa、 TAT-apoptin 單用和聯閤應用對 U87細胞增殖的影響； AO/EB 熒光染色與流式細胞儀檢測對 U87細胞凋亡的影響；建立裸鼠 C6膠質瘤皮下移植模型,計算 Rapa、TAT-apoptin 單獨及聯閤作用下的抑瘤率。結果 Rapa 與 TAT-apoptin 單獨用藥均能抑製 U87細胞的增殖,呈劑量依賴性,聯閤用藥組細胞增殖率明顯低于單獨用藥組(P ﹤0.05)；聯閤用藥組凋亡狀態比單獨用藥更明顯,呈晚期凋亡形態,細胞凋亡率顯著高于單獨用藥組(P ﹤0.01)；在體內實驗中,聯閤用藥組抑瘤率為65.5％,雷帕黴素與 TAT-凋亡素單獨用藥抑瘤率分彆為29.59％,24.4％,前者比後者高1倍(P ﹤0.05)。結論 Rapa 與 TAT-ap 聯閤用藥可增彊對膠質瘤細胞增殖的抑製作用,促進膠質瘤細胞的凋亡,產生協同的抗腫瘤作用。
목적：연구뢰파매소(Rapamycin, Rapa)화조망소(TAT-apoptin, T-ap)연합응용대신경효질류적치료작용。방법용 MTT 실험비교 Rapa、 TAT-apoptin 단용화연합응용대 U87세포증식적영향； AO/EB 형광염색여류식세포의검측대 U87세포조망적영향；건립라서 C6효질류피하이식모형,계산 Rapa、TAT-apoptin 단독급연합작용하적억류솔。결과 Rapa 여 TAT-apoptin 단독용약균능억제 U87세포적증식,정제량의뢰성,연합용약조세포증식솔명현저우단독용약조(P ﹤0.05)；연합용약조조망상태비단독용약경명현,정만기조망형태,세포조망솔현저고우단독용약조(P ﹤0.01)；재체내실험중,연합용약조억류솔위65.5％,뢰파매소여 TAT-조망소단독용약억류솔분별위29.59％,24.4％,전자비후자고1배(P ﹤0.05)。결론 Rapa 여 TAT-ap 연합용약가증강대효질류세포증식적억제작용,촉진효질류세포적조망,산생협동적항종류작용。
Objective To investigate the inhibitory effects of rapamycin in combination with TAT-apoptin on malignant glioma. Methods MTT assay was used to detect the proliferation rate of U87 cells treated by rapamycin alone or combined with TAT-apoptin. Cell apoptosis was detected by AO/ EB Fluorescence and Annexin V/ PI staining. C6 xenograft glioma models were constructed in nude mice, which were given injection of rapamycin alone or combined with TAT-apoptin. The effects of rapamycin alone or combined with TAT-apoptin on tumor growth were explored. Results Rapamycin and TAT-apoptin could separately inhibit the proliferation of U87 cells in a dose-depend-ent manner. The two drugs combined could significantly inhibit the cell proliferation when compared with single drug treatment (P ﹤ 0. 05), and the apoptosis rate of U87 cells in the combined group was significantly increased when compared with that in the single drug group (P ﹤ 0. 01) . The rate of tumor inhibition was 65. 5% in combined group, about one fold higher than 29. 49% in rapamy-cin group and 24. 11% in T-apoptin. Conclusion Rapamycin in combination with TAT-apoptin can increase the inhibitory effects on the proliferation of glioma cells, promote the cell apoptosis and have synergistic anti-tumor effects.
